WORLD-EUROPE | Wellcome, Gates Foundation to fund late-stage research of TB vaccine candidate

A baby receives the Bacillus Calmette-Guerin (BCG) vaccine for tuberculosis (TB) during a national immunization for children program at an integrated services post in Banda Aceh on June 9, 2022.(AFP/Chaideer Mahyuddin)

Wellcome and the Bill & Melinda Gates Foundation announced on Wednesday funding to advance a tuberculosis (TB) vaccine candidate, the M72/AS01E (M72), through a Phase III clinical trial.

Memento Maxima Digital Marketing
@[email protected]
SPACE RESERVE FOR ADVERTISEMENT

The M72 could potentially become the first new vaccine to help prevent pulmonary TB, a form of active TB, in more than 100 years if it is proven effective.

To support the M72 Phase III clinical trial, which will cost an estimated US$550 million, Wellcome is providing up to $150 million while the Gates Foundation will fund the remainder, about $400 million.

.

to Read Full Story/ Click to read: https://www.thejakartapost.com/world/2023/06/29/wellcome-gates-foundation-to-fund-late-stage-research-of-tb-vaccine-candidate.html.

Elly Burhaini Faizal (The Jakarta Post)
Jakarta   ●   Thu, June 29, 2023

It's only fair to share...